Imunon hit its highest levels in nearly three years Tuesday, fueled by its announcement to present Phase 2 OVATION 2 study ...

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

Imunon (IMNN) announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 shares of its common stock or pre-funded warrants in lieu therof and short ...

IMUNON, Inc. raises $3.25 million through the sale of shares and warrants, potentially totaling $9.75 million with full warrant exercise. IMUNON, Inc. has completed a private placement raising ...

IMUNON initiates Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer; Phase 2 data accepted for ASCO presentation. IMUNON, Inc. has initiated the first trial site for its Phase 3 ...

About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas ® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that ...

Shares of Imunon Inc. skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001. The stock IMNN ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...